Valbenazine, also known as NBI-98854 and MT-5199, is a potent and selective VMAT2 inhibitor. NBI-98854 is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines. NBI-98854 is promising agent for the treatment of tardive dyskinesia.NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. These results support the phase 3 clinical trials of NBI-98854 now underway
Gano, Kyle W. Preparation of pyrido[2,1-a]isoquinoline derivatives for treating hyperkinetic disorders. Assignee Neurocrine Biosciences, Inc., USA. WO 2008058261. (2008).
